Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason T Kimata

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 22, 2025
Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIVIlaria Facchi, Nicola Di Trani, Camden Caffey, et al.
Journal of Virology|September 15, 2007
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapyZandrea Ambrose, Sarah Palmer, Valerie F Boltz, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 24, 2023
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaquesFernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
NPJ Vaccines|July 21, 2024
A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudovirusesSyamala Rani Thimmiraju, Rakesh Adhikari, JeAnna R Redd, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
Nature Communications|June 11, 2026
Statewide multi-year wastewater sequencing reveals dual origins of HIV-1 signalJustin R Clark, Dylan Chirman, Harihara Prakash, et al.
Vaccine|May 14, 2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Biorxiv : the Preprint Server for Biology|November 11, 2020
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 22, 2025
Localized inflammasome inhibition mitigates foreign body response to subcutaneous long-acting antiretroviral therapy for HIVIlaria Facchi, Nicola Di Trani, Camden Caffey, et al.
Journal of Virology|September 15, 2007
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapyZandrea Ambrose, Sarah Palmer, Valerie F Boltz, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 24, 2023
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaquesFernanda P Pons-Faudoa, Nicola Di Trani, Simone Capuani, et al.
Protein Expression and Purification|October 24, 2021
Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidateWen-Hsiang Chen, Jeroen Pollet, Ulrich Strych, et al.
NPJ Vaccines|July 21, 2024
A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudovirusesSyamala Rani Thimmiraju, Rakesh Adhikari, JeAnna R Redd, et al.
Pharmaceutics|October 21, 2020
Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic ImplantFernanda P Pons-Faudoa, Nicola Di Trani, Antons Sizovs, et al.
Nature Communications|June 11, 2026
Statewide multi-year wastewater sequencing reveals dual origins of HIV-1 signalJustin R Clark, Dylan Chirman, Harihara Prakash, et al.
Vaccine|May 14, 2022
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernJeroen Pollet, Ulrich Strych, Wen-Hsiang Chen, et al.
Biorxiv : the Preprint Server for Biology|November 11, 2020
SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in MiceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics|April 13, 2021
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in miceJeroen Pollet, Wen-Hsiang Chen, Leroy Versteeg, et al.
Pageof 8